Fig. 3From: A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancerPaclitaxel PK. Preliminary paclitaxel PK data for the nine study patients are not appreciably different from those reported in the literatureBack to article page